Clovis Oncology Inc (NASDAQ: CLVS) stock closed at $4.92 on 12/30/20 after a major increase of 10.6%. Moreover, above average trading volume at 144% of normal accompanied the advance. Relative to the market the stock has been extremely weak over the last nine months and has declined -6.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, CLVS is expected to be a major Value Eraser.
Clovis Oncology is currently unrated.
The stock is currently unrated.